An Education Session featuring three experts discussed germ cell tumors, the use of surveillance to reduce treatment toxicities, and the lack of data on high-dose chemotherapy versus other salvage therapy options.
Numerous ongoing or planned clinical trials will help determine whether matching treatments to molecular or genomic profiles of patients actually results in improved outcomes. The Signature program has led to rapid start-up time for eight phase II trials testing targeted Novartis compounds.
Biomarkers suggestive of adaptive immune activity were seen in mRCC patients who had better clinical outcomes with nivolumab in a phase I trial. Upregulation of CTLA-4 and PD-L2 was seen during treatment with nivolumab, suggesting the potential for combination with ipilimumab in patients with mRCC.
Advances made in next generation sequencing have allowed germline mutations to be increasingly identified in tumors and normal DNA. The significance of these findings, including whether results arising from germline testing should be returned to patients, was discussed during this session.